1982 Volume 24 Issue 6 Pages 655-663
Twenty-four hemodialized patients with severe anemia (Ht<20%), were treated with a new androgenic steroid, Mepitiostane, orally at the daily doses of 20mg for 4 months. As for anemia, increase of Ht over 3% after the therpy, and decrease of blood transfusion amount with in crease of Ht over 3% were considred to be effective Eighteen out of 22cases (81.8%) responded to Mepitiostane. As for side effects, development of impaired liver function seemed less marked in the course of treatment with Mepitiostane than the other steroids. In the course of the treatment, serum ferritin decreased prominently, therefore iron supplement was recommended during therapy, Serum erythropoietin was fell after the treatment Increase of appetite, body weight and TIBC was observed, meanwhile serum creatinine increased significantly. As a result, Mepitiostane is well effective on anemia with minor side effects.
